Briefing on ARTS to Secretary Hazel October 2017

Size: px
Start display at page:

Download "Briefing on ARTS to Secretary Hazel October 2017"

Transcription

1 Agenda -DMAS -DBHDS -VDH -Final discussion Briefing on ARTS to Secretary Hazel October

2 Medicaid Addiction and Recovery Treatment Services (ARTS) Partial Hospitalization Intensive Outpatient Programs Opioid Treatment Case Management Magellan will continue to cover community-based substance use disorder treatment services for feefor-service members Residential Treatment Inpatient Detox Effective April 1, 2017 Addiction and Recovery Treatment Services (ARTS) Peer Recovery Supports effective July 1, 2017 Peer Recovery Supports Crisis Intervention All Community- Based SUD Services will be Covered by Managed Care Plans A fully integrated Physical and Behavioral Health Continuum of Care 2

3 Budgeted Costs for ARTS Benefit Funding Included in 2016 Appropriations Act as Substance Use Disorder funding: $2.5 million GF ($5 million total funds) $8.3 million GF ($16.6 million total funds) This year's Medicaid forecast is not changing these projected costs. 3

4 Health Systems Asks for Health Systems and Health Plans Add inpatient detox beds and Addiction Detox Units Add DBHDS Detox License to Inpatient Psych Units Develop Intensive Outpatient and Partial Hospitalization Programs Provide integrated MAT in outpatient clinics buprenorphine-waivered physicians with integrated behavioral health providers and peer supports Encourage physicians and behavioral health providers to attend VDH Addiction Disease Management sessions Commercial Health Plans Implement CDC Opioid Prescribing Guidelines for Chronic Pain that FFS implemented on 7/1/16 and Medicaid plans will implement 12/1/16 Offer similar rates for addiction treatment as Medicaid plans to catalyze expansion of addiction treatment 4

5 Payment Model for Office-Based Opioid Treatment Providers Service Description Codes Physician Visit Counseling H0014 MAT Induction CPT E/M Code: Established Patient H0020 Opioid Treatment - individual, group counseling and family therapy / prescribing and medication oversight Care Coordination G9012 Substance Abuse Care Coordination Peer Supports H0038 Peer Support Services S9445 Peer Patient Education Individual S9446 Peer Patient Education - Group Urine Drug Screen G0477-G0483 Examples: Hepatitis B Test (86704), Hepatitis C test (86803), HIV Labs Test (86703), Pregnancy Test (81025), PPD (86585) 5

6 OBOT Providers will be Credentialed by Health Plans Care Team Requirements Buprenorphine-waivered physician may practice in a variety of practice settings including primary care clinics, outpatient health system clinics, psychiatry clinics, FQHCs, CSBs, Health Departments, and physician s offices On site licensed behavioral health provider providing counseling to patients receiving buprenorphine MAT Requirements Buprenorphine monoproduct prescribed only to pregnant women. All other patients receive buprenorphine/naloxone or naltrexone products Maximum daily buprenorphine/naloxone dose 16 mg unless documentation of compelling clinical rationale for higher dose up to maximum of 24 mg No tolerance to other opioids, soma, stimulants, or benzodiazepines except for patients already on benzodiazepines for 3 months during a relapse or tapering plan 6

7 OBOT Providers will be Credentialed by Health Plans Risk Management and Adherence Monitoring Requirements Random urine drug screens, a minimum of 8 times per year. Virginia Prescription Monitoring Program checked at least quarterly. Opioid overdose prevention education including naloxone. Patients seen at least weekly when initiating treatment. Periodic utilization of unused medication and opened medication wrapper counts Benefits No PA required for buprenorphine or buprenorphine/naloxone Buprenorphine-waivered physician in the OBOT can bill all Medicaid plans for substance abuse care coordination code (monthly per member payment) for members with moderate to severe opioid use disorder receiving MAT. Can bill for Certified Peer Recovery Support specialists 7

8 Buprenorphine Prior Authorization Requirements Uniform Requirements Adopted by FFS and Managed Care Plans Diagnosis of Opioid Use Disorder, and > 16 years of age; and Prescriber s personal DEA and XDEA numbers are required; and Individual is participating is psychosocial counseling Maximum of 16 mg per day Initial authorization for 3 months; subsequent authorizations for 6 months No set time limit or duration of treatment Buprenorphine only products for pregnant women Patient is locked-in to prescribing physician and dispensing pharmacy No concurrent use with benzodiazepines, tramadol, carisoprodol, other opiates or stimulants Urine drug testing at least 4 times per 6 months 8

9 Implementation of CDC Guidelines for Prescribing Opioids Uniform, Stream-lined Prior Authorization Forms for All Short acting opioids > 14 days or 90 MME and long-acting opioids Will require PMP check and urine drug screen Increase access to Naloxone Available without PA and no quantity limits Naloxone injection and Naloxone nasal spray (Narcan ) Include non-opioid pain relievers on all MCO formularies without PA Lidocaine patches Capsaisin topical gel SNRIs including duloxetine Gabapentin and pregabalin (Lyrica ) NSAIDs including oral and topicals (diclofenac gel) Baclofen Tricyclic antidepressants (TCAs) Buprenorphine patches and buccal film for pain 9

10 Implementation of CDC Guidelines for Prescribing Opioids Uniform Quantity Limits (QL) for Short and Long-acting Opioids QL based on maximum of 90 MME (morphine milligram equivalents) PA required for any individual drug dose > 90 MME or cumulative dosage > 120 MME Concomitant use of benzodiazepine with opioid will trigger a PA Provider and Member Education Prescriber Letters Identify patients receiving benzos and opioids concomitantly Identify patients receiving >90 MME individual drug opioid doses Identify patients receiving >120 MME cumulative opioid doses Member Letters Identify members that meet PUMS 2 criteria and provide lock-in information or educational materials regarding opioid use 10

11 Aligning ASAM Criteria with DBHDS Licensing Requirements 11

12 ASAM Training Offerings Two Day Skill Building (10 trainings total) Ten two-day skill building sessions intended primarily for those providing assessments, designing and implementing programs, providing case management services, and managing quality assurance. Sessions are limited to 40 participants. each. One Day Administrative Sessions (2 Total) Two one-day sessions intended for nonclinical managers, such as CEOs, CFOs, and CIOs. One Day Coach Trainings (2 Total) Two one-day sessions to train coaches who will provide ongoing continuity to assure that Virginia providers are consistently utilizing the ASAM Criteria Registration Fees $50 per person for CSBs and contract agencies $200 per person for MCOs and contract providers. The ASAM Criteria, 3rd Edition, Up to three participants can share a copy. 12

13 ASAM TWO DAY TRAINING SCHEDULE DATE LOCATION REGISTRATION November 1-2, 2016 November 3-4, 2016 VA Housing Development Authority Dorey Park Recreation Center, Henrico TRAINING FULL TRAINING FULL December 5-6, 2016 Fairlington Center, Arlington OPEN December 7-8, 2016 Northern VA, TBA OPEN January 3-4, 2017 Southwest VA, TBA OPEN January 5-6, 2017 Southwest VA, TBA OPEN January 31-February 1, 2017 Region Ten CSB, Charlottesville, VA OPEN February 2-3, 2017 The Cove, Winchester, VA OPEN February 27-23, 2017 Tidewater Area, TBA OPEN March 1-2, 2017 Tidewater Area, TBA OPEN 13

14 DBHDS Certified Peer Recovery Specialists (CPRS) Peer Certification HB 583 (2016) authorizes DBHDS Commissioner to certify individuals as peer providers in accordance with regulations adopted by the Board of Behavioral Health and Developmental Services GA Appropriations Act directed DBHDS to promulgate emergency regulations for implementing the CPRS program and designation. DBHDS is in the process of developing a curriculum for Certified Peer Recovery Specialists (CPRS). Curriculum is expected to be established by January DBHDS is developing CPRS training timelines to support the implementation of peer services in the ARTS Waiver, for July 1, CPRS Train the Trainer sessions will begin in the spring of 2017 and will focus on the 5 regions to ensure broad availability and statewide workforce development. 14

15 DBHDS Certified Peer Recovery Specialists (CPRS) CPRS Structure and Development DBHDS is working with DHP and DMAS to develop regulations on the certification of peer recovery specialists. DBHDS is promulgating regulations that define the educational and experience requirements for certification, as well as certification bodies that will be accepted in Virginia. Proposed legislation and subsequent regulations will institute the requirement for CPRS to register with DHP and establish DHP authority to renew registration, investigate complaints, and implement any disciplinary actions. Registration will be required for a CPRS to be eligible for the payment of services by DMAS. 15

16 Health Systems DBHDS Asks Consider developing peer support programs in Emergency Department settings Implement CDC Opioid Prescribing Guidelines Encourage behavioral health providers to become ARTS providers or Encourage ARTS providers (and those who will become ARTS providers) to attend ARTS ASAM trainings. 16

17 Addiction Disease Management Removing the Barriers for Integration and Application into Outpatient Clinical Practice Statewide Trainings for Healthcare, Behavioral Health, and Clinical Administration Professionals Statewide trainings within the 7 MCO regions: January 2016 to April 2017 Intended Audience: Practicing MDs/DOs, APNs, PAs, medical students, behavioral health professionals, substance abuse professionals, and administrators supporting provider clinical practice Content Virginia Medicaid s Addiction and Recovery Treatment Services (ARTS) new benefit; Assessment, screening, and monitoring of the integrated care patient at risk for, or with a history of, addiction Discovery of addiction as an underlying disease Integrated outpatient clinical practice and behavioral health care interventions for addiction disease management (ADM) Specialty track content for removing barriers and challenges to integration, coordination, and operational practice National framework content for obtaining the waiver to prescribe buprenorphine Development of a seamless OBOT primary care, behavioral health, and business model Framework Integration of ASAM criteria; Utilization of PCSS MAT criteria; Meets the requirement of the federal DATA 2000 law Physicians will complete the 8 hour SAMSHA funded Provider Clinical Support System: MAT criteria online and in-person hours to meet the requirement for providers to obtain the waiver to prescribe buprenorphine in their practice for treatment of opioid addiction. Free CMEs available for online and live trainings, including Virginia specific content 17

18 Association Meeting Presentations: Psychiatric Society of Virginia: October 2016 Medical Society of Virginia: October 2016 Community Care Network of VA October 2016 Va Academy of Family Physicians: February 2017 Specialty Trainer Expert Areas: Medical Behavioral Health Administrative Training Areas: Medical: Clinical and business delivery Behavioral Health: Primary to BH Integration Administrative: Operations Training Opportunities October 2016: ADM Sneak Peek Key SME experts to provide a Sneak Peak on the benefits and barriers to implementing ADM in an office setting, and on state level resources for the provider team November 2016: ADM Train-the-Trainer Model In each MCO region, selected champions will be trained to target and to educate local physicians, behavioral health providers, and administrators in the ADM curricula January-April 2017: ADM Train-the-Provider Model Approximately 4 trainings will be hosted in each of the 7 MCO regions Anticipated Reach: Approximately 300 providers. 18

19 VDH Addiction Workgroup Purpose: To convene VDH staff in an effort to analyze current policy, program, intervention, and data management related to the Opioid Epidemic and Addiction in the Commonwealth. Workgroup meets approximately every 6 weeks VDH Addiction Workgroup participants: OEpi, OCME, OEMS, OHE, OFHS, OCOM, ORCE Invited guests: include other state agencies DBHDS, OHP, Fusion Center, etc. Key areas of focus: Data management and availability related to Addiction/Opioid Epidemic Training needs in the state for providers Analysis of OCME OD Death data and trends Gap Analysis for overall VDH response by Office and Subject area Collaboration activities with other agencies, partners Policy Needs Workgroup meets approximately every 6 weeks Next meeting: November

ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE

ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE Matthew Keats, MD, MMM Behavioral Health Medical Director Virginia Department of Medical Assistance Services October 26, 2017 www.dmas.virginia.gov

More information

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS) Department of Medical Assistance Services 600 East Broad Street, Suite 1300 Richmond, Virginia 23219 MEDICAID MEMO http://www.dmas.state.va.us TO: All Prescribing Providers, Pharmacists, and Managed Care

More information

VIRGINIA MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) OFFICE BASED OPIOID PROVIDER (OBOT) PAYMENT MODEL 3 rd Annual Mental Health Summit

VIRGINIA MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) OFFICE BASED OPIOID PROVIDER (OBOT) PAYMENT MODEL 3 rd Annual Mental Health Summit 1 VIRGINIA MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) OFFICE BASED OPIOID PROVIDER (OBOT) PAYMENT MODEL 3 rd Annual Mental Health Summit May 9, 2017 Virginians Covered by Medicaid and CHIP

More information

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC 1 VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC Virginia Association of Counties November 14, 2016 The Honorable William A. Hazel, Jr., M.D. Secretary of Health and Human Resources 1999 - Estimated drug

More information

VIRGINIA MEDICAID PERSPECTIVE ON BEST PRACTICES IN THE TREATMENT OF OPIOID USE DISORDER

VIRGINIA MEDICAID PERSPECTIVE ON BEST PRACTICES IN THE TREATMENT OF OPIOID USE DISORDER VIRGINIA MEDICAID PERSPECTIVE ON BEST PRACTICES IN THE TREATMENT OF OPIOID USE DISORDER Katherine Neuhausen, MD, MPH Chief Medical Officer Virginia Department of Medical Assistance Services October 26,

More information

ADDICTION AND RECOVERY OPIOID CRISIS

ADDICTION AND RECOVERY OPIOID CRISIS ADDICTION AND RECOVERY OPIOID CRISIS Ke Shawn Harper, MS Substance Use Disorder Analyst Virginia Department of Medical Assistance Services www.dmas.virginia.gov The Opioid Addiction Emergency In Virginia:

More information

PERSPECTIVE FROM VIRGINIA: SUCCESS ADDRESSING THE OPIOID CRISIS THROUGH MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS)

PERSPECTIVE FROM VIRGINIA: SUCCESS ADDRESSING THE OPIOID CRISIS THROUGH MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PERSPECTIVE FROM VIRGINIA: SUCCESS ADDRESSING THE OPIOID CRISIS THROUGH MEDICAID ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) Katherine Neuhausen, MD, MPH, Chief Medical Officer Virginia Department

More information

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure

Addiction and Recovery Treatment Services (ARTS) Reimbursement Structure Page 1 of 13 Billing Code Service Name Service Description ASAM Level APPROVED CODES & RATES APPROVED BY CENTERS FOR MEDICARE AND MEDICAID SERVICES AUGUST 25, 2017 Community Based Care Unit Lengths Annual

More information

Medicaid and the Opioid Crisis

Medicaid and the Opioid Crisis Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers

More information

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit

Revised 9/30/2016. Primary Care Provider Pain Management Toolkit Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral

More information

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine

More information

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention

Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention The Accountable Community for Health of King County Addressing the Opioid Crisis Workgroup: Treatment and Overdose Prevention May 7, 2018 1 Opiate Treatment & Overdose Prevention Project Goal Immediate:

More information

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and

More information

Virginia Medicaid Peer Support Services UM Guideline

Virginia Medicaid Peer Support Services UM Guideline Virginia Medicaid Peer Support Services UM Guideline Subject: Virginia Medicaid Peer Support Services Current Effective Date: 08/24/2017 Status: Final Last Review Date: 10/23/2018 Description Peer Supports

More information

An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder

An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder An Alternative Payment Model Concept for Office-based Treatment of Opioid Use Disorder CONTENTS I. Need for an Alternative Payment Model for Opioid Use Disorder and Addiction... 2 A. Improving Services

More information

DMAS UPDATE ON GAP PROGRAM. Cindi B. Jones, Director, DMAS House Appropriations Committee September 18, 2017

DMAS UPDATE ON GAP PROGRAM. Cindi B. Jones, Director, DMAS House Appropriations Committee September 18, 2017 DMAS UPDATE ON GAP PROGRAM Cindi B. Jones, Director, DMAS House Appropriations Committee September 18, 2017 Bridging the Mental Health Coverage GAP GAP s Inception The Governor s Access Plan 1 of a 10

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January

More information

From Medicaid Transformation Approved Project Toolkit, June 2017

From Medicaid Transformation Approved Project Toolkit, June 2017 From Medicaid Transformation Approved Project Toolkit, June 2017 Domain 3: Prevention and Health Promotion Transformation projects within this domain focus on prevention and health promotion to eliminate

More information

State Opioid Response (SOR) Grant

State Opioid Response (SOR) Grant State Opioid Response (SOR) Grant Adam Bucon, LSW DMHAS Provider Meeting September 20, 2018 Philip D. Murphy Governor Shereef M. Elnahal Commissioner Sheila Y. Oliver Lt. Governor NJ Opioid Statistics

More information

BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES

BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES BUPRENORPHINE/NALOXONE THERAPY DOM CLINICAL GUIDELINES AND RECOMMENDED CHANGES BACKGROUND In September 2012, the Division of Medicaid (DOM) implemented criteria through electronic prior authorization (PA)

More information

Addressing the Opioid Epidemic through a Public Health Lens

Addressing the Opioid Epidemic through a Public Health Lens Addressing the Opioid Epidemic through a Public Health Lens MONICA BHAREL, MD, MPH MASSACHUSETTS COMMISSIONER OF PUBLIC HEALTH VISION Optimal health and well-being for all people in Massachusetts, supported

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Effective Date: 04.18 Last Review Date: 04.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description

More information

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018

More information

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. 201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone. RELATES TO: KRS 311.530-311.620, 311.990 STATUTORY AUTHORITY: KRS

More information

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS

New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS New Initiatives to Expand Access to Medication Assisted Treatment in NYS OASAS Charles W. Morgan, MD, DFASAM, FAAFP Medical Director New York State Office of Alcoholism and Substance Abuse Services February

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

OPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION

OPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION OPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION The Department of Human Services (DHS) is implementing 50 opioid use disorder (OUD) Health Homes or Centers of Excellence (COE)

More information

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm

More information

Public Policy Statement on the Regulation of Office-Based Opioid Treatment

Public Policy Statement on the Regulation of Office-Based Opioid Treatment Public Policy Statement on the Regulation of Office-Based Opioid Treatment Background Office-based opioid treatment (OBOT) commonly refers to outpatient treatment services provided outside of licensed

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral

More information

Addressing the Opioid Crisis Policy Recommendations

Addressing the Opioid Crisis Policy Recommendations Addressing the Opioid Crisis Policy Recommendations The Pew Charitable Trusts Pew is an independent nonprofit, nonpartisan research and policy organization. Tools: Research Partnerships Technical assistance

More information

Aetna s Initiative on the Opioid Epidemic

Aetna s Initiative on the Opioid Epidemic Aetna s Initiative on the Opioid Epidemic Christopher James D.O., M.P.H. Medical Director, BH- Mid-Atlantic Territory (JamesC1@aetna.com) July 23, 2017 HHS Data on Epidemic Every Day in the U.S. More than

More information

The Opioid Crisis: Effectiveness of State Responses

The Opioid Crisis: Effectiveness of State Responses The Opioid Crisis: Effectiveness of State Responses Gordon H. Smith, Esq. Maine Medical Association American Society of Medical Association Counsel Mauna Lani Bay, November 2017 Opioids: the difficult

More information

Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic

Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic Battling Opioid Addiction: Public Policy and Healthcare Strategies for an Epidemic Speakers: Margarita Pereyda, M.D., Principal, Moderator: Carl Mercurio, Information Services September 29, 2015 HealthManagement.com

More information

MAGELLAN VA MEDICAID/DMAS RATES

MAGELLAN VA MEDICAID/DMAS RATES Psychiatric Diagnostic Evaluation no medical svcs* Psychiatric Diagnostic Evaluation no medical svcs* Psychotherapy w/ patient, 30 min* Psychotherapy w/ patient, 30 min* Psychotherapy w/ patient, 45 min*

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy

More information

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q) Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and

More information

NCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Medicaid Transformation Project

NCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Medicaid Transformation Project NCACH RAPID CYCLE APPLICATION: OPIOID PROJECT North Central Accountable Community of Health - Introduction The North Central Accountable Community of Health (NCACH) is accepting applications from partners

More information

ADDING EVEN MORE SUBSTANCE TO MANAGED CARE

ADDING EVEN MORE SUBSTANCE TO MANAGED CARE HEALTH WEALTH CAREER ADDING EVEN MORE SUBSTANCE TO MANAGED CARE OPTIMIZING MEDICAID TO RESPOND TO SUBSTANCE USE DISORDERS NATIONAL ACADEMY FOR STATE HEALTH POLICY 30TH ANNUAL STATE HEALTH POLICY CONFERENCE

More information

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC

SC MAT ACCESS. Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC SC MAT ACCESS Medication Assisted Treatment Academic Community Capacity Expansion for Sustainable Success Kathleen Brady, MD, PhD, VPR, MUSC Overdose Death Rates from Opiates Most important sign of a

More information

Kentucky s Strategic Action Plan. Katherine Marks, Ph.D. August 16, 2018

Kentucky s Strategic Action Plan. Katherine Marks, Ph.D. August 16, 2018 Kentucky s Strategic Action Plan Katherine Marks, Ph.D. August 16, 2018 OUTLINE The state & the need The organization of a response The action plan THE STATE AND THE NEED KENTUCKY 4.4 million people 35

More information

Oregon Opioid Overdose Prevention Initiative

Oregon Opioid Overdose Prevention Initiative Oregon Opioid Overdose Prevention Initiative Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Association of Hospitals & Health Systems February 2017

More information

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19 Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS

TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health

More information

Curbing Prescription Drug Abuse in Medicaid

Curbing Prescription Drug Abuse in Medicaid Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance

More information

Opioid Treatment Program Reimbursement Re-bundling Proposal

Opioid Treatment Program Reimbursement Re-bundling Proposal Opioid Treatment Program Reimbursement Re-bundling Proposal Maryland Department of Health and Mental Hygiene April 22, 2016 The Department reviewed close to 50 letters and emails submitted by stakeholders

More information

MAGELLAN VA MEDICAID/DMAS RATES

MAGELLAN VA MEDICAID/DMAS RATES DESCRIPTION CODE Age or Setting Modifier PHYSICIAN PSYCHOLOGIST LEVEL SPECIALIST Psychiatric Diagnostic Evaluation no medical svcs* 90791 IP w/ or w/o GT $104.18 $93.76 $70.32 $70.32 Psychiatric Diagnostic

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the

More information

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18 Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction

More information

TN Opioid Program. Erica Schlesinger, Pharm.D

TN Opioid Program. Erica Schlesinger, Pharm.D TN Opioid Program Erica Schlesinger, Pharm.D Nothing to disclose Disclosures TN Together Governor Haslam s Plan Prevention Establishes limits, decreases supply and dosage of prescription opioids Limits

More information

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP

THA Medication Safety Summit. Wesley Geminn, PharmD, BCPP THA Medication Safety Summit Wesley Geminn, PharmD, BCPP Current Trends: Overdose Deaths in 2017 72,000 Or 197 per day 8 per hour National Opioid Overdose Statistics https://www.drugabuse.gov/related-topics/trendsstatistics/overdose-death-rates

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

The CARA & Buprenorphine Prescribing for APNs & PAs

The CARA & Buprenorphine Prescribing for APNs & PAs The CARA & Buprenorphine Prescribing for APNs & PAs William J. Lorman, JD, PhD, MSN, PMHNP-BC, CARN-AP FIAAN Assistant Clinical Professor, Drexel University, Philadelphia, PA V. P. & Chief Clinical Officer,

More information

Opioid Analgesic Treatment Worksheet

Opioid Analgesic Treatment Worksheet Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797

More information

Addiction Recovery Treatment Services (ARTS): Billing Best Practices. December 2017

Addiction Recovery Treatment Services (ARTS): Billing Best Practices. December 2017 Addiction Recovery Treatment Services (ARTS): Billing Best Practices December 2017 Substance Use Billing Best Practices Following the guidelines, requirements, and protocols for billing substance use services

More information

Opioid epidemic and PEHP

Opioid epidemic and PEHP Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe

More information

Opiate Use Disorder and Opiate Overdose

Opiate Use Disorder and Opiate Overdose Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5

More information

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)

Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication

More information

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists Background Opioid medications are effective at treating certain types of pain,

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling

MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN. State Senator Alberta Darling MANAGING THE COSTS OF THE OPIOID EPIDEMIC IN WISCONSIN State Senator Alberta Darling A NATIONAL PROBLEM According to the 2014 National Survey on Drug Use and Health: 435,000 Americans have used heroin

More information

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology

More information

Strategic Plan

Strategic Plan 2017-18 Strategic Plan 1 Strategic Planning Process The Summit County Opiate Task Force has made great strides in addressing the opiate crisis in the last few years. More than 100 Summit County citizens

More information

Frequently Asked Questions about Florida s Opioid STR Grant

Frequently Asked Questions about Florida s Opioid STR Grant Frequently Asked Questions about Florida s Opioid STR Grant 1. Are there any administrative dollars for the MEs? A. No. 2. Is there funding available for outreach and awareness to advise the community

More information

RI Centers of Excellence for the

RI Centers of Excellence for the RI Centers of Excellence for the Treatment of Opioid Use Disorder COE CODAC Behavioral Healthcare Linda Hurley President/CEO 9-18-17 for the Warren Alpert Medical School of Brown University RI s Strategic

More information

Opioid Prescribing Improvement Program

Opioid Prescribing Improvement Program Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing

More information

HHSC LAR Request. Substance Abuse Disorder Coalition. Contact Person: Will Francis Members:

HHSC LAR Request. Substance Abuse Disorder Coalition. Contact Person: Will Francis Members: HHSC LAR Request Substance Abuse Disorder Coalition Contact Person: Will Francis wfrancis.naswtx@socialworkers.org Members: NAMI Texas Children s Defense Fund Texas Communities for Recovery National Association

More information

WHAT YOU NEED TO KNOW TO ABOUT AB 474

WHAT YOU NEED TO KNOW TO ABOUT AB 474 WHAT YOU NEED TO KNOW TO ABOUT AB 474 PRESENTED BY: NEVADA STATE BOARD OF OSTEOPATHIC MEDICINE 2275 Corporate Circle, Suite 210 Henderson, NV 89074 702-732-2147 Fax 702-732-2079 Web Site: www.bom.nv.gov

More information

Fighting Today s Opioid Epidemic

Fighting Today s Opioid Epidemic Fighting Today s Opioid Epidemic Establish in 1966 as a Public Health Department Location: Rock Falls, IL/Whiteside County Population: Whiteside County 2015--57,079 Serving Rural IL: Primarily Whiteside,

More information

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain Centers for Disease Control and Prevention National Center for Injury Prevention and Control THE EPIDEMIC Chronic Pain and Prescription Opioids 11%

More information

Prescription Monitoring Program (PMP)

Prescription Monitoring Program (PMP) 06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid

More information

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. 2017 State Targeted Response to the Opioid Crisis Grants QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D. H.R.6-21st Century Cures Act The 21st Century Cures Act is a United States law enacted

More information

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder

Clinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare

More information

Maine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016

Maine s Response to the Opiate Crisis. Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Maine s Response to the Opiate Crisis Christopher Pezzullo, DO State Health Officer Maine DHHS Maine CDC November 12, 2016 Required Disclosure Text Font typically Times New Roman at least 20 point Try

More information

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3) NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau

More information

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers

Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Maine s New Opioid Prescribing Law & the Opioid Crisis: Implications for Providers Gordon H. Smith, Esq., Executive Vice President Maine Medical Association May 3, 2016 Facing the Opioid Crisis Today Opioid

More information

PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018

PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018 PITTSBURGH MERCY: COMPREHENSIVE INTEGRATED CARE JUNE 6, 2018 AN ENHANCED MEDICAL HOME MODEL FOR THE SMI POPULATION Comprehensive Care Patient Centered Care Coordinated Care Accessible Services Quality

More information

Division of Mental Health and Addiction Services

Division of Mental Health and Addiction Services Division of Mental Health and Addiction Services A DAM BUCON, LSW DMHAS Mission DMHAS, in partnership with consumers, family members, providers and other stakeholders, promotes wellness and recovery for

More information

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02. Clinical Policy: (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: 09.01.17 Last Review Date: 02.18 Line of Business: Medicaid See Important Reminder at the end of this policy for

More information

TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown

TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown TESTIMONY Of Pam Gehlmann Executive Director/ Assistant Regional Director Pinnacle Treatment Centers Alliance Medical Services-Johnstown Center for Rural Pennsylvania On Confronting the Heroin Epidemic

More information

Management Options for Opioid Dependence:

Management Options for Opioid Dependence: Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice

More information

MICIS 2017 REPORT January 1 - December 31, 2017

MICIS 2017 REPORT January 1 - December 31, 2017 MICIS 2017 REPORT January 1 - December 31, 2017 MICIS, the Maine Independent Clinical Information Service, has been providing evidence-based prescribing education in Maine since 2008. 2017 Program The

More information

SAMHSA/HHS: An Update on the Opioid Crisis

SAMHSA/HHS: An Update on the Opioid Crisis SAMHSA/HHS: An Update on the Opioid Crisis Elinore F. McCance-Katz, MD, PhD Assistant Secretary for Mental Health and Substance Use Substance Abuse and Mental Health Services Administration U.S. Department

More information

The Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018

The Opioid Epidemic and How It is Impacting the Workplace. July 24, 2018 The Opioid Epidemic and How It is Impacting the Workplace July 24, 2018 In 2016 CDC reports a 300% increase in opioid prescription sales since 1999 without an overall change in reported pain National Safety

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for

More information

BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County

BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County BERNALILLO COUNTY OPIOID ABUSE ACCOUNTABILITY SUMMIT Turning the Curve on Opioid Abuse in Bernalillo County NMPHA Annual Conference April 2, 2014 Marsha McMurray-Avila Coordinator, Bernalillo County Community

More information

Opioid Task Force Kick-Off Meeting. February 29, 2016

Opioid Task Force Kick-Off Meeting. February 29, 2016 Opioid Task Force Kick-Off Meeting February 29, 2016 Scope of the Opioid Problem and Data Review Olivia Kasirye, MD, MS County Public Health Officer OVERVIEW The Opioid Epidemic Opioid Task Force Development

More information

Changing Course: statewide efforts to combat the opioid epidemic in California

Changing Course: statewide efforts to combat the opioid epidemic in California Changing Course: statewide efforts to combat the opioid epidemic in California Kelly Pfeifer, MD kpfeifer@chcf.org April 26, 2018 State of Reform conference STAT Special Report: 52 weeks, 52 faces Obituaries

More information

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States

More information

New Guidelines for Prescribing Opioids for Chronic Pain

New Guidelines for Prescribing Opioids for Chronic Pain New Guidelines for Prescribing Opioids for Chronic Pain Andrew Lowe, Pharm.D. CAPA Meeting October 6, 2016 THE EPIDEMIC Chronic Pain and Prescription Opioids 11% of Americans experience daily (chronic)

More information

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.19 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of

More information

PHMC Integrated Health Services Overview

PHMC Integrated Health Services Overview PHMC Integrated Health Services Overview Dinetta Armstrong Managing Director Health Services Who is PHMC? Nonprofit public health institute Serving the city/region since 1972 Provides direct services,

More information

SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS

SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS SUBSTANCE USE DISORDER TREATMENT AND REFERRAL PROCESS Presented by: John M. Connolly, Ph.D. Acting Deputy Director Los Angeles County Health Agency Department of Public Health Substance Abuse Prevention

More information

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as

More information

Governor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018

Governor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018 Governor Raimondo s Task Force on Overdose Prevention and Intervention May 9, 2018 DIRECTOR NICOLE ALEXANDER-SCOTT, MD, MPH, RHODE ISLAND DEPARTMENT OF HEALTH DIRECTOR REBECCA BOSS, MA, RHODE ISLAND DEPARTMENT

More information